Amundi’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Amundi’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-64,873	Closed	-$3.83M	–	2100
2023 Q4	$3.83M	Buy	64,873 +53,915	+492%	+$3.03M	﹤0.01%	1039
2023 Q3	$613K	Sell	10,958 -2,812	-20%	-$100K	﹤0.01%	1381
2023 Q2	$524K	Sell	13,770 -17,502	-56%	-$721K	﹤0.01%	1377
2023 Q1	$1.16M	Buy	31,272 +27,676	+770%	+$1.24M	﹤0.01%	1241
2022 Q4	$148K	Sell	3,596 -855	-19%	-$55.3K	﹤0.01%	1556
2022 Q3	$313K	Buy	4,451 +3,602	+424%	+$267K	﹤0.01%	1408
2022 Q2	$51K	Buy	+849	New	+$54K	﹤0.01%	1538
2022 Q1	–	Sell	-72,330	Closed	-$8.59M	–	1740
2021 Q4	$8.59M	Sell	72,330 -3,525	-5%	-$547K	0.01%	877
2021 Q3	$13.4M	Sell	75,855 -31,041	-29%	-$4.99M	0.01%	773
2021 Q2	$17.3M	Buy	+106,896	New	+$17.2M	0.01%	711

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Amundi's MRTX Position: Q1 2024 in Review

Amundi sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 64,873 shares — an estimated $3.83M sold.

Amundi first reported a position in MRTX in Q2 2021 and held it in 10 quarters. The position peaked at $17.3M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Amundi reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Amundi sold 64,873 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.83M.
Amundi first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Amundi's Mirati Therapeutics, Inc. Common Stock position peaked at $17.3M in Q2 2021.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.